Get in touch:

Kirklees: 01484 469691

Calderdale: 01422 341764

PrEP (Pre Exposure Prophylaxis)

Posted on 23rd January 2017 by The Brunswick Centre

Information about PrEP and how to access it before it becomes available on the NHS

PrEP (Pre Exposure Prophylaxis)

Pre-exposure prophylaxis is a course of HIV drugs taken before sex to reduce the risk of getting HIV. It is taken as a tablet once a day and research suggests that if it is taken every day as directed, it is very effective in preventing HIV transmission.

PrEP is intended for people who are at high risk of getting HIV. This includes people with a partner who is HIV positive or those who have multiple sexual partners and find it hard to use condoms. 

The pill contains two medicines that are also used to treat HIV and if taken every day reduce the risk of getting HIV.

The new HIV initiative is joint between NHS England and Public Health England, and follows the recent Court of Appeal ruling that NHS England, alongside local authorities, has the power, although not the obligation, to fund the provision of anti-retroviral drugs for the prevention of HIV, known as pre-exposure prophylaxis (PrEP).

The first phase of implementation will be the launch of a large scale clinical trial in early financial year 2017/18. Although the evidence around the clinical effectiveness of PrEP is strong, advice from Public Health England has highlighted significant outstanding implementation questions that should be answered prior to using PrEP in a sustained way on a substantial scale in England. These questions will be answered by the clinical trial, paving the way for full rollout.

It is anticipated that the clinical trial phase will include at least 10,000 participants over the next three years. NHS England will fully fund the cost of the clinical trial phase and will work in partnership with local authorities, the Local Government Association and Public Health England to implement the findings as part of a wider national rollout.

Detailed planning will now take place to ensure the launch and the clinical trial phase can begin as swiftly as possible. Up to £10 million will be made available over the next three years to fund all aspects of the trial. Next steps will include asking both the manufacturer of the branded PrEP drug Truvada, as well as generic manufacturers to make proposals to participate in the trial.

For more information call NHS England press office on 0113 825 0958 or Public Health England on 0207 654 8400

Until PrEP is made available you can buy it through a private service. Use the link below to find out how to purchase PrEP yourself:

Prepster have produced an ebooklet which includes everything you need to know about PrEP . Please click on the link below.

For further information about any of the above please click on the link below.